Anaplastic large cell lymphoma (ALCL)

Jean-Loup Huret

Genetics, Dept Medical Information, UMR 8125 CNRS, UMR 8125 CNRS, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: August 2001

Online updated version : http://AtlasGeneticsOncology.org/Anomalies/AnaplLargeCellLymphID2103.html

DOI: 10.4267/2042/37786

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 2001 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Note

Anaplastic large cell lymphoma can be classified into:
1-Primary systemic ALK+ ALCL;
2-Primary systemic ALK- ALCL;
3-Primary cutaneous ALCL. (see in paragraph Pathology).

The 2 first categories are defined according to the involvement (or not) of ALK in fusion proteins with various partners (see below); ALK+ ALCL cases are sometimes called ALK lymphomas, or ALKomas.

ALK+ ALCL can be further divided into t(2;5) cases, with NPM1-ALK fusion protein which localises both in the cytoplasm and in the nucleus, and t(2;Var), involving various partners and ALK, and a cytoplasmic localization of the fusion protein; the latter are called "cytoplasmic only" ALK+ ALCL.

ALKCL may also arise from transformation of another lymphoma (mycosis fungoides, peripheral T-cell lymphoma, ...); these ALCL are called secondary ALCL, and they bear a poor prognosis.

Clinics and pathology

Epidemiology

ALCL represent about 5% of non Hodgkin lymphomas (NHL) in adults, and 15 % of pediatric NHL (i.e. 20-30 % of large cell lymphomas in children). ALK+ ALCL represent 50 to 60 % of ALCL cases. ALK+ ALCL predominantly affect young male patients (most cases occur before the age of 40 yrs), while ALK- ALCL is found in older patients (median age around 50 yrs) of both sex.

Clinics

ALK+ ALCL presents as an aggressive disease with systemic signs, and extranodal sites (bone marrow, skin, bone, soft tissues, and organs); less aggressive presentation in ALK- ALCL cases (but a worse prognosis, see below).

Note: ALK+ ALCL without the t(2;5) (so called cytoplasmic only ALK cases) show clinical features similar to those of classical ALK+ ALCL. Were found in a recent series: mean age: 19 yrs, range 4 to 45 yrs; male/female ratio: 1.5, presentation with advanced disease (stage III-IV in 9 of 15 cases), systemic symptoms (11/15), and frequent involvement of extranodal sites.

Pathology

3 main histopathological types are found:

The common type, characterized by large lymphoid cells with horseshoe shaped nuclei with many nucleoli, and large cytoplasm; may be ALK + or - ALCL;

The small cell type, together with the above described cells, show small and medium sized cells; almost exclusively ALK+ cases;

The lymphohistiocytic type also contains a number of reactive histiocytes, which, earlier, lead to the misdiagnosis of malignant histiocytosis; almost always ALK+ cases;

The lymphohistiocytic type also contains a number of reactive histiocytes, which, earlier, lead to the misdiagnosis of malignant histiocytosis; almost always ALK+ cases.

All the 3 forms contain large cells, positive for CD30 (on the cell membrane and the golgi); they are mostly epithelial memban antigen (EMA) positive.

Most cases are T-cell cases (often cytotoxic T-cells), or may be null cases, the null cases often involving the T-cell; B-cell cases may belong to a different category; ALK+/IgA+ immunoblastic large B-cell lymphomas could exist.

Aside are primary cutaneous anaplasic large cell lymphomas, a disease with indolent clinical course, negative for ALK, lacking the t(2;5) or variant translocations, close to the benign lymphomatoid papulosis.
Note: There are cases where the differential diagnosis between Hodgkin disease (HD) -where CD30 is also strongly expressed- and ALCL is difficult (cases previously called ALCL-HD like).

**Prognosis**

ALK+ ALCL have a favourable prognosis, whichever the ALK partner is: 70% to 80% 5 yr survival, while ALK- ALCL cases have a much poorer prognosis (5 yr survival in only 30% -40%). ALK+ cases without NPM1 involvement.

**Genetics**

Note

The genetic background in ALK- cases remains unknown.

ALK+ cases are the result of the formation of a hybrid gene between ALK and either NPM1 (in 80% of the cases), or, more rarely: MSN, TPM3, ATIC, TFG, or CLTCL1 (these latter being"cytoplasm only" or cytoplasmic and/or membrane restricted ALK+ ALCL).

**Cytogenetics**

**Cytogenetics morphological**

(t;2;5)(p23;q35) in the classical form with NPM1 involvement on chromosome 5, t(X;2)(q11;p23), t(1;2)(q25;p23), inv(2)(p23;q35), t(2;3)(p23;q21), or t(2;22)(p23;q11.2) can also be found.

**Genes involved and proteins**

Note

These translocations involve ALK in 2p23, and either MSN in Xq11, TPM3 in 1q25, ATIC in 1q35, TFG in 3q21, NPM1 in 5q35, or CLTCL1 in 22q11.

**ALK**

**Location**

2p23

**Protein**

1620 amino acids; 177 kDa; glycoprotein (200 kDa mature protein); membrane associated tyrosine kinase receptor.

**MSN**

**Location**

Xq11

**Protein**

576 amino acids, 68 kDa; cytoskeleton protein; binds to the plasma membrane and interacts with actin.

**TPM3 (tropomyosin alpha chain)**

**Location**

1q25

**Protein**

284 amino acids, 33 kDa; coiled coil structure; role in Calcium dependant actin-myosin interaction.

**ATIC**

**Location**

2q35

**Protein**

591 amino acids, 64 kDa; bifunctional purine biosynthesis: 9th and 10th step of the de novo purine synthesis.

**TFG (tropomyosin receptor kinase-fused gene)**

**Location**

3q21

**Protein**

406 amino acids, 44 kDa; widely expressed.

**Somatic mutations**

Apart from the TFG-ALK herein described, TFG is also known to be fused to NTRK1 in a subset of thyroid papillary carcinomas.

**NPM1**

**Location**

5q35

**Protein**

Nuclear localisation; RNA binding nucleolar phosphoprotein involved in preribosomal assembly.

**CLTCL1**

**Location**

22q11.2

**Protein**

1640 amino acids, 187 kDa; component of the coat of vesicles originated from the plasma membrane or the golgi.

**Result of the chromosomal anomaly**

**Hybrid gene**

**Description**

5’ partner - 3’ ALK.

**Fusion protein**

**Description**

N-term amino acids from the partner gene fused to the 562 C-term amino acids from ALK (i.e. the entire cytoplasmic portion of ALK with the tyrosine kinase domain); homodimerization of the fusion protein.
To be noted

ALK and some of the above ALK partners, or closely related genes, are found implicated in inflammatory myofibroblastic tumours; this is a new concept, that 2 different types of tumour may result from the same chromosomal/genes rearrangement.

References


This article should be referenced as such: